Full Press Release Details
Biomaterials Ltd. Announces Pricing of Initial Public Offering
Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE
American: RGNT) ("Regentis", or the "Company"), a regenerative medicine company dedicated to developing innovative
tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the pricing of its
initial public offering (the "Offering") of 1,250,000 ordinary shares ("Ordinary Shares") at an initial public
offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and estimated
offering expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an
additional 187,500 Ordinary Shares to cover over-allotments, if any.
Ordinary Shares are expected to begin trading on the NYSE American LLC on December 4, 2025, under the symbol "RGNT". The
Offering is expected to close on or about December 5, 2025, subject to satisfaction of customary closing conditions.
Company intends to use the net proceeds from the Offering primarily for development activities, including the completion of its pivotal
trial, and preparation of the PMA submission for GerlinC, and also for corporate purposes including the repayment of certain debt and
deferred compensation payments.
is acting as sole book-running manager for the Offering.
Registration Statement on Form F-1 (File No. 333-285692) and amendments thereto relating to the Ordinary Shares being sold in the Offering
was filed with the U.S. Securities and Exchange Commission ("SEC") and became effective, as amended, on November 12, 2025. The
Offering is being made only by means of a prospectus. Copies of the preliminary prospectus and the final prospectus, when available,
may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The preliminary prospectus
was filed with the SEC and is available, and the final prospectus will be filed with the SEC and will be available on the SEC's
website located at http://www.sec.gov.
press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
Regentis Biomaterials Ltd.
Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore
the health and enhance the quality of life of patients. The Company's current efforts are focused on orthopedic treatments using
its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue. GelrinC is Regentis' cartilage
injury therapeutic based on a unique hydrogel, erodible and resorbable, matrix of polyethylene glycol. The Company's lead product
candidate, GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into a temporary implant in the knee for the treatment of painful
injuries to articular knee cartilage. GelrinC was approved as a device with a Conformit Europ ene mark in Europe, (CE
mark number 3900600CE02). The Company plans to start commercialization efforts in Europe to bring its product to market, while being
focused in parallel on completing its pivotal study for obtaining United States Food and Drug Administration approval. For more information,
please visit https://www.regentis.co.il/
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words, and include the expected start of trading of the Ordinary Shares on the NYSE American LLC, the expected
use of proceeds, and the expected date of closing of the Offering. Forward-looking statements are based on Regentis' current expectations
and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties
affecting Regentis, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission
("SEC"), including, but not limited to, the risks detailed in the section titled "Risk Factors" in the final
prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of
this date, and Regentis undertakes no duty to update such information except as required under applicable law.
Investor Relations Inquiries